Emergency evidence suggests XCL1 is becoming a significant biomarker for multiple cancers including HCC,13 squamous cell carcinoma,11 and intestinal tumor,14 and targeting XCL1 could potentially induce anti-tumor immune responses. Here, XCL1 is linked to hepatocellular carcinoma.